M&T Bank Corp Trims Stock Position in AstraZeneca PLC (NASDAQ:AZN)

M&T Bank Corp cut its position in AstraZeneca PLC (NASDAQ:AZN) by 6.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 251,109 shares of the company’s stock after selling 16,721 shares during the quarter. M&T Bank Corp’s holdings in AstraZeneca were worth $19,564,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the company. FMR LLC raised its stake in AstraZeneca by 1.1% in the third quarter. FMR LLC now owns 23,117,447 shares of the company’s stock valued at $1,801,080,000 after purchasing an additional 258,477 shares in the last quarter. Fisher Asset Management LLC raised its position in shares of AstraZeneca by 5.3% during the 3rd quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock valued at $816,509,000 after buying an additional 524,175 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of AstraZeneca by 16.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock worth $266,565,000 after acquiring an additional 488,644 shares during the last quarter. Clearbridge Investments LLC grew its position in AstraZeneca by 5.8% in the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after acquiring an additional 186,010 shares in the last quarter. Finally, Bank of Montreal Can increased its stake in AstraZeneca by 109.6% in the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock valued at $238,397,000 after acquiring an additional 1,605,758 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

AstraZeneca Stock Up 1.4 %

Shares of NASDAQ AZN opened at $65.35 on Friday. The firm’s fifty day moving average is $69.02 and its 200 day moving average is $76.31. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The company has a market cap of $202.63 billion, a price-to-earnings ratio of 31.27, a PEG ratio of 1.19 and a beta of 0.45.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.87 earnings per share. On average, equities research analysts expect that AstraZeneca PLC will post 4.11 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AZN has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.